Jessica Atkinson
Corporate Officer/Principal chez Cox Paving Co. LP
Profil
Jessica Atkinson currently works as a Contracts Administrator at Cox Paving Co. LP.
She is currently the Chief Business Officer at ImmuneID, Inc.
Postes actifs de Jessica Atkinson
| Sociétés | Poste | Début |
|---|---|---|
Cox Paving Co. LP
 Cox Paving Co. LP Construction MaterialsNon-Energy Minerals Cox Paving Co. LP provides general contracting services. The firm specializes in asphalt rubber blending services for hot mix asphalt producers as well as perform sealcoat operations using own asphalt rubber mix. The company was founded in 1965 and is headquartered in Blanco, TX. | Corporate Officer/Principal | - |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Corporate Officer/Principal | 17/10/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cox Paving Co. LP
Cox Paving Co. LP Construction MaterialsNon-Energy Minerals Cox Paving Co. LP provides general contracting services. The firm specializes in asphalt rubber blending services for hot mix asphalt producers as well as perform sealcoat operations using own asphalt rubber mix. The company was founded in 1965 and is headquartered in Blanco, TX. | Non-Energy Minerals |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |
